Select Bibliography

Filter by any of these (after searching):

Richardson, Paul G.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 2 items

Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN AFT-29

Voorhees, Peter M. , Kaufman, Jonathan L. , Laubach, Jacob ... - IMW - - 2019

Abstract - Primary - Primary - Myeloma - AFT-29 (GRIFFIN)

Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVD) improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): GRIFFEN study update (AFT-29)

Voorhees, Peter M. , Kaufman, Jonathan L. , Laubach, Jacob ... - ASH - Blood - 2019

Abstract - Secondary - Primary - Myeloma - AFT-29 (GRIFFIN)